Horizon Therapeutics PLC (HZNP)
| Market Cap | 20.71B |
| Revenue (ttm) | 2.19B |
| Net Income (ttm) | 280.04M |
| Shares Out | 224.77M |
| EPS (ttm) | 1.25 |
| PE Ratio | 73.65 |
| Forward PE | 19.80 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $92.14 |
| Previous Close | $87.74 |
| Change ($) | 4.40 |
| Change (%) | 5.01% |
| Day's Open | 88.32 |
| Day's Range | 87.74 - 92.41 |
| Day's Volume | 1,393,193 |
| 52-Week Range | 45.01 - 97.20 |
DUBLIN--(BUSINESS WIRE)--Horizon ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company.
As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...
As investors were so righteously reminded on Friday, many of the day-to-day Wall Street prognostications and strategy calls are almost always “best guesses” or data-based “assumptions.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in May: Bank of America Securities 2021 Health Care Confere...
DUBLIN--(BUSINESS WIRE)--New analysis of UPLIZNA® (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD) has been published.
Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare...
Horizon Therapeutics reported a mixed quarter Wednesday, but raised its sales target for 2021. Still, HZNP stock dipped after the open.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $0.03, which missed the estimat...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Guidance to Incorporate Recently Acquired Viela Bio
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc ranked #4 in overall corporate reputation among pharmaceutical and biotech companies.
CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout un...
NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion G...
Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.
Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again?
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Hor...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomit...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new NMOSD data being presented at the American Academy of Neurology's 73rd Annual Meeting.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April.
DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an in...
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (peg...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual glo...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multipl...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked No. 1 on the Fortune Best Workplaces in Biopharma 2021 list. This is the fifth consecutive year Horizon has bee...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2021 by Great Place to Work Ireland, ranking No. 12 ...
The shares of Horizon Therapeutics PLC (NASDAQ:HZNP) are down 3.4% at $91.29 at last check.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 41st Annual Health Care Confere...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of a month-long virtual storytelling experience to elevate the diverse voices and faces of the rare disease co...
Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.
The biopharmaceutical company released its latest quarterly update.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Horizon Therapeutics (NASDAQ:HZNP) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 128.57% over the past year to $1.28, which beat the esti...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.
Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Barrick Gold...
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK--(BUSINESS WIRE)--Horizon Therapeutics expands partnership with Medidata to speed clinical trial start-up and completion, using a broad range of technology solutions.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2020 financial results will be released on Wednesday, Feb. 24, 2021. Following the ...
Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.
Horizon Pharma saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96. The post Horizon Pharma Sees Rising Composite Rating To 96 appeared first on Investor's Business Daily.
Horizon Therapeutics PLC (NASDAQ: HZNP), a rare and rheumatic diseases drug company, announced a multibillion-dollar deal Monday to snap up Viela Bio Inc (NASDAQ: VIE). What Happened: Horizon said it ha...
Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first qua...
About HZNP
Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chroni... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Jul 28, 2011 |
| Stock Exchange NASDAQ | Ticker Symbol HZNP |
Financial Performance
In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.
Analyst Forecasts
According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 114.18, which is an increase of 23.92% from the latest price.